Hui-Ming Chang, MD, MPH

Hui-Ming Chang, MD, MPH

Medicine

Associate Research Professor
Co-Director, Center for Precision Medicine

Academic Information

Associate Research Professor
Co-Director, Center for Precision Medicine

Research Interests

  • Onco-Cardiology
  • Chemobrain
  • Pain Mechanism
  • Sentrin/SUMO
  • Medical Education
  • Evidence-based Medicine

Areas of Expertise

  • Pain Medicine
  • Clinical Practice Guidelines

Related Links

Education & Training

Medical School

National Taiwan University, Harvard Chan School of Public Health

Internship

George Washington University Medical Center

Residency

Boston University Medical Center

Fellowship

Boston Children’s Hospital, Harvard Medical School

Board Certification

Pain Medicine

Medical School

National Taiwan University

School of Public Health

Harvard Chan School of Public Health

Publications

1. Yeh ET, Chang HM Oncocardiology-Past, Present, and Future: A Review, JAMA Cardiol. 2016 Dec 1;1(9):1066-1072

2. Chang HM, Yeh ET Potential of Oncocardiology-Reply, JAMA Cardiol. 2017 July 1;2(7):818

3. Yeh ET, Chang HM Cancer and Clot: Between a Rock and a Hard Place, J Am Coll Cardiol 2017 August 22; 70 (8): 939-941                                  

4. Chang HM, Moudgil R, Scarabelli T, Okwuosa T, Yeh ET Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1, J Am Coll Cardiol November 14;70(20):2536-2551, 2017

5. Chang HM, Okwuosa T, Scarabelli T, Moudgil R, Yeh ET Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2, J Am Coll Cardiol November 14;70 (20):2552-2556, 2017

6. Chang HM  NIH, Precision Medicine Initiative, All of Us Research Program, Use cases February 2018 
What are the long-term cardiovascular effects of cancer therapy? Do childhood cancer survivors have reduced cardiac functions?

https://allofusresearchpriorities.ideascale.com/a/dtd/What-are-the-long-term-cardiovascular-effects-of-cancer-therapy-Do-childhood-cancer-survivors-have-reduced-cardiac-functions/197154-44880#idea-tab-comments
What are the genetic, comorbid risk factors, and anticancer agents that contribute to heart failure after cancer therapy

https://allofusresearchpriorities.ideascale.com/a/dtd/What-are-the-genetic-comorbid-risk-factors-and-anticancer-agents-that-contribute-to-heart-failure-after-cancer-therapy/196492-44880#idea-tab-comments

Cancer and clot: What is the incidence and timing of thromboembolism after cancer diagnosis

https://allofusresearchpriorities.ideascale.com/a/dtd/Cancer-and-clot-What-is-the-incidence-and-timing-of-thromboembolism-after-cancer-diagnosis/196911-44880#idea-tab-comments

7. Yang FM, Zuo Y, Zhou W, Xia C, Hahm B, Sullivan M, Cheng J, Chang HM, Yeh ET sNASP Inhibits TLR Signaling to Regulate Immune Response in Sepsis.  J of Clinical Investigation. In press. J Clin Invest. 2018 Jun 1;128(6):2459-2472. doi: 10.1172/JCI95720. Epub 2018 May 7.